Influenza

Catharine Paules, Kanta Subbarao

Influenza is an acute respiratory illness, caused by influenza A, B, and C viruses, that occurs in local outbreaks or seasonal epidemics. Clinical illness follows a short incubation period and presentation ranges from asymptomatic to fulminant, depending on the characteristics of both the virus and the individual host. Influenza A viruses can also cause sporadic infections or spread worldwide in a pandemic when novel strains emerge in the human population from an animal host. New approaches to influenza prevention and treatment for management of both seasonal influenza epidemics and pandemics are desirable. In this Seminar, we discuss the clinical presentation, transmission, diagnosis, management, and prevention of seasonal influenza infection. We also review the animal–human interface of influenza, with a focus on current pandemic threats.

Lancet 2017; 390: 697–708

Published Online
March 13, 2017
http://dx.doi.org/10.1016/S0140-6736(17)30129-0

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
(C Paules MD, K Subbarao MBBS)

Correspondence to:
Dr Kanta Subbarao, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, MSC 3203, Bethesda, MD, 20892, USA
ksubbarao@niaid.nih.gov

Introduction

Influenza is an acute respiratory illness that has been recognised since the 16th century and spreads rapidly through communities in outbreaks.[1] Two forms of influenza occur globally: epidemic (seasonal or interpandemic) influenza caused by influenza A and B viruses, and sporadic pandemics caused by influenza A viruses. These epidemiological forms of influenza result from distinct mechanisms of antigenic variation in the surface glycoproteins of the virus, referred to as antigenic drift and antigenic shift. Antigenic drift is a continuous process that occurs in both influenza A and B viruses and results from the accumulation of point mutations in the viral haemagglutinin and neuraminidase genes. Antigenic drift is driven by antibody-mediated selective pressure and a high rate of viral mutations due to the absence of proofreading ability of the viral RNA-dependent RNA polymerase.[1,2] Antigenic drift permits the virus to escape immunity induced through previous exposure or vaccination, resulting in seasonal epidemics.[1] In temperate regions, influenza epidemics occur annually with a predictable seasonality, whereas in tropical regions they can occur all year round with unpredictable peaks.[3] Influenza epidemics spread rapidly with an average reproductive number of 1·28 and an attack rate of 10–20%, depending on age.[4–6] Influenza outbreaks are often first recognised in children presenting with febrile illness.[1] An increase in hospital admissions and respiratory or circulatory deaths are reported as the epidemic progresses. A typical influenza epidemic peaks within 2–3 weeks of onset and lasts 5–6 weeks.[1] Seasonal influenza accounts for thousands of deaths and hospital admissions annually in the European Union and the USA, with an even greater impact in developing countries.[7–11] Influenza epidemics in which H3N2 strains predominate are associated with the highest overall morbidity and mortality. The panel summarises the risk factors associated with severe illness, complications, or mortality due to influenza.

Antigenic shift is a sporadic event, restricted to influenza A viruses, and refers to the introduction into human beings of a novel virus strain to which a large proportion of the population does not have immunity.[1] If the novel influenza virus spreads efficiently and sustainably from person to person, it can cause a global pandemic. Four influenza pandemics have occurred in the past 100 years: H1N1 Spanish influenza in 1918, H2N2 Asian influenza in 1957, H3N2 Hong Kong influenza in 1968, and H1N1 swine influenza in 2009. Additionally, H1N1 viruses re-emerged in 1977 but did not cause a pandemic. During each pandemic, a novel influenza virus arose, either directly from an avian host (1918), via reassortment between an avian virus and a circulating human strain (1957 and 1968), or through influenza virus reassortment in pigs (2009), and spread through the human population, causing substantial morbidity and mortality, which was often associated with bacterial pneumonia.[1,2,20] The most severe pandemic occurred in 1918 and caused over 50 million deaths worldwide.[5,20] In the years following each pandemic, descendants of the pandemic strain established a new viral lineage in human beings and either replaced or co-circulated with previously circulating strains. Currently, the pandemic 2009 H1N1 (H1N1pdm09) influenza A virus is co-circulating with H3N2 and influenza B viruses.

Search strategy and selection criteria

We consulted a search specialist at the National Institutes of Health (NIH) library and searched the Cochrane Library and PubMed for articles published in the past 5 years (from Feb 1, 2011, to May 16, 2016) pertaining to influenza and each of the topics discussed in the Seminar. Search terms included "influenza", "influenza and systematic reviews", "influenza and diagnosis", "influenza and therapy", "influenza and prevention and control", "influenza and pandemic", "influenza and epidemiology", "influenza and clinical", "influenza and vaccines", "influenza and pandemic", "influenza and transmission", and "influenza and risk factors". The most relevant and recently published references were then selected to comply with the reference number limitations. Relevant textbook chapters and articles older than 5 years were included when indicated. Additional references that could be of interest to readers but are not directly cited in the article are included in the appendix.

See Online for appendix

Panel: Factors associated with increased morbidity and mortality from in uenza[1,18,19]

Age
- “ˆ —Š Ž ‹˜Š ‰ † ™‰” ˜ • Ž †™‰ ‹ ˆ Ž ˜ ŽŽ”“‰ Ž › Ž‘‰ Š †•‘† “ž Š † — ˜
- “ˆ —Š Ž ‹˜Š ‰ ™ ‹– Ž”™ † ž ‰ ŠŽ Ž–š Š Ž Ÿ †š “ Œ‰ š‘ †™Œ Š ‰ 20–40 years)
- “ˆ —Š Ž ‹˜Š ‰ Ž †™‰ ‹ ˆ Ž ˜ ŽŽ • Ž ‘ ‰Ž —š Š Œ™Š• –‹ Ž Š †é • † — ™ Ž ˆ š ‘ † — Ž children <2 years of age)

Pregnancy
- Ž Œ–• Š ‹ • ™— ‡ Ž in third trimester
- Ž Œ–• ™ † ‡ Ž Š™—Ž› “ $ ‰ † “ ‰$ • † “ ‰ Š ’ Ž ˆ ˜
- “ˆ —• Š † • ˜Š ‰ ‹ ˆ Ž ˜ ˜Ž ˜“Š —Ž›˜Š ‰Š $• † “ ‰ Š† Ž‰ š — Ž “ Œ interpandemic in uenza
- ”‹”Š –™š†™ ˆ ” Ž Š — Š Œ ‡ † “Š ‰ ’ Ž ™ ™ Š• ‰ ™ Ž – - š Š “ Ÿ †

Immunocompromised state
- ” — ™ Ž˜Ž ™ Ž Ž†Ž˜Š‰ Ž › Ž ‰ ‰ š —Œ”Š Š Œ — † “ ˜ • ‘† Ž ‰ Œ † “ transplant, or chemotherapy
- ” — ™ Ž˜Ž ™ Ž Ž†Ž˜Š‰ Ž › Ž‰ š ™†‹œ • † › Š ” œ ˆ Š ˆ ” š “ †™ ‰ — Š not on antiretrovirals
- ” — ™ Ž˜Ž ™ Ž Ž† †Š‰Ž”Š ™ • Š’ – š “ Š Â ’ ” ‰ Ž Š‰ Ž Ž Œ ™ Ž ” “ ˜ ½ but dependent on the degree of immune suppression

Medical comorbidity
- — Š”‹ Š “Ž Š ‰ Ž ˆ† ” — ‡ Ž ‰ Ž ™ Ž“ Š ˆ ‘ š ‰ ˜ Ž Š Œ Š † Œ Š“ Ž ™ Ž › Š dysfunction, pulmonary disease, cardiovascular disease, renal disease, liver disease ‰ Ž † ‡•Š Š™ Ž ˜ ½ • š ˜ Š †½‰ Š ˜ Ž ™ ž ä † œ ŽŽ ™ Š ‰ Š ‰ – ™ Ž ™ ž
- “ ‰ Ž › Ž”‰ Š † Ž ‰ Ž ™ Ž Ž ™ Š ‰ – Ž ‡ Š ‰ ’ Ž ˜ ™ Ž ” • Ž †™ ‰ mortality

Genetic susceptibility
- “ˆ —Š Ž ‹˜Š ‰ Ž †™‰ ‹ ˆ Ž ˜ ‹ Ž Ž - š Š Ž Ÿ † ‰ Ž › Ž ‰ š † Š Ž “ Œ † Š “Š ˜ of interferon-induced transmembrane protein 3 (IFITM3); mechanism is under investigation; IFITM restricts cellular entry of in uenza viruses and is an important interferon-stimulated gene

The virus

In uenza viruses belong to the Orthomyxoviridae family and are divided into three types (A, B, and C).[1,21,22] In uenza A and B viruses cause seasonal epidemics, whereas in uenza C viruses generally cause mild disease. In uenza A viruses are further classi ed into subtypes on the basis of the antigenic properties of their two surface glycoproteins, haemagglutinin and neuraminidase. 16 haemagglutinin and nine neuraminidase subtypes of in uenza A viruses have been isolated from birds (H1 to H16 and N1 to N9), and RNA of an additional two haemagglutinin and neuraminidase subtypes has been identi ed in bats (H17 and H18, and N10 and N11).[23] A similar animal reservoir does not exist for in uenza B viruses but two antigenically distinct lineages of in uenza B viruses—Victoria and Yamagata—co-circulate in human beings.[1]

In uenza viruses are enveloped particles that contain a single-stranded, segmented RNA genome.[1,22] In uenza A and B viruses possess eight gene segments, which encode at least 17 proteins. The haemagglutinin protein mediates binding of in uenza virus to its receptors, sialyloligosaccharides on the host cell.[1,22,24] Human in uenza viruses preferentially bind to 2,6-linked sialyloligosaccharide receptors, which predominate in the human upper respiratory tract, whereas avian in uenza viruses bind to 2,3-linked sialyloligosaccharide receptors, which are more prevalent in the lower respiratory tract.[25] The neuraminidase protein facilitates viral particle release by cleaving sialyloligosaccharide residues from the host cell surface.[1,22] The viral haemagglutinin, neuraminidase, and matrix 2 proteins are targets of the protective antibody response, and the nucleoprotein and matrix 1 proteins are targets of the cellular immune response.[26]

Transmission

The epidemiological success of in uenza viruses lies in their ability to spread e ciently from person to person. Three mechanisms of in uenza transmission have been identi ed—aerosol, droplet, and contact transmission—and the relative importance of each mechanism is a matter of debate.[1,27] When an infected individual sneezes or coughs, they expel infectious particles ranging from 0·1 m to 100 m in diameter.[28] Fine particles (aerosols) and droplet nuclei, generated from the rapid desiccation of larger droplets, have a diameter less than 5 m and are able to remain airborne for minutes to hours, but are vulnerable to changes in temperature and humidity.[29,30] They can be inhaled and deposited in the upper or lower respiratory tract.[1,27] Larger droplets are deposited in the upper respiratory tract or settle quickly in the environment, generally within 2–3 m of the infected individual. Contact transmission from fomites to mucosal surfaces can occur.[27,31] The virus remains infectious for a short time on the hands but can remain infectious on non-porous surfaces in the environment for up to 48 h. Previously, most in uenza transmission events were thought to occur via large droplets. Below, we describe data supporting a role for aerosol transmission of in uenza viruses and the implications for infection control policy.

Ferrets experimentally infected by aerosol inoculation have in uenza infections that more closely resemble naturally acquired human illness than ferrets inoculated intranasally.[32] Experimental infections of human volunteers also support a role for aerosol transmission of in uenza, and the minimum infectious dose via aerosol is lower than when the virus is administered through intranasal drops (0·6–3·0 median tissue culture infectious doses [$TCID_{50}$] for aerosol transmission compared with 127–320 $TCID_{50}$ for intranasal inoculation).[33] In uenza viruses have been detected in the air from patients' rooms, urgent care centres, and emergency rooms, and epidemiological observations point to a substantial contribution of aerosol transmission in outbreak settings.[1,29,30,34,35] Moser and colleagues[36] described the spread of in uenza aboard an

airliner where the ventilation system was shut o for several hours; 38 (72%) of the 53 passengers developed in uenza. Aerosol transmission has also been suggested to contribute to the spread of in uenza in a tuberculosis ward in California, USA, a medical ward in Hong Kong, a skilled nursing facility in Wisconsin, USA, and in household contacts in China.[1,37–39]

WHO and the US Centers for Disease Control and Prevention (CDC) recommend the use of a surgical mask when caring for a patient with in uenza; respirators (N95 or powered air purifying respirators) are only recommended during aerosol-generating procedures such as bronchoscopy or intubation.[40,41] Surgical masks and respirators appear to provide health-care workers with a similar degree of protection from transmission of in uenza viruses.[28,42] Data suggest that the use of surgical masks can prevent most in uenza transmission events in health-care settings with appropriate air exchange, good hand hygiene practices, and immunity to seasonal in uenza through previous exposure or vaccination. However, aerosols can play an important role in in uenza transmission. Thus, respirator use is recommended during aerosol-generating procedures and might also be prudent for all patient care activities during an in uenza pandemic when population immunity is low.

Clinical presentation

The presentation of seasonal in uenza ranges from an asymptomatic infection to a fulminant illness, depending on the characteristics of both the host and virus.[1,12,21,43] Symptoms appear suddenly after an incubation period of 1–2 days and are characterised by various systemic features, including fever, chills, headache, myalgia, malaise, and anorexia, accompanied by respiratory symptoms, including non-productive cough, nasal discharge, and sore throat.[1,12,21,43] Ocular symptoms can also be present and include photophobia, conjunctivitis, lacrimation, and pain with eye movement.[43]

When present, fever is the most important physical nding and temperatures can be as high as 41°C in the rst 24 h of illness.[1,12,21,43] Physical examination can reveal a toxic appearance with prominent ushing of the face and hyperaemic mucous membranes.[43] A clear nasal discharge might be present and eyes might be injected and watery. Small cervical lymph nodes might be palpable and tender. About 25% of cases have di use rhonchi or rales upon auscultation of the lungs. Fever and associated systemic symptoms typically last for 3 days but can persist for up to 8 days. Cough and malaise can persist for up to 2 weeks after resolution of fever.

The presentation of in uenza in children can di er from that in adults.[21,43] Children have higher maximum temperatures than do adults, and infants can present with an undi erentiated fever or febrile seizures. Laryngotracheobronchitis (croup), bronchiolitis, and bronchitis can occur. Children report severe myalgia in the calf muscles, and myositis is a more frequent complication than in adults.[1,21,43] Gastrointestinal symptoms are seen with higher frequency in children than in adults.[1,21,43]

Viral shedding typically begins during the incubation period, peaking in the rst 1–2 days of clinical illness, and decreasing to undetectable amounts after a week, correlating well with the severity of clinical symptoms.[44] Children and immunocompromised patients shed virus for a longer duration than do healthy adults.[43,45] There is a paucity of data regarding the shedding of in uenza virus in asymptomatic infections.[46]

Pulmonary complications

Primary in uenza-associated pneumonia was rst documented during the 1957 pandemic, although it was suspected during the 1918 pandemic.[1,43,47] Patients present with typical in uenza symptoms, followed by rapid respiratory decompensation. Chest imaging reveals di use bilateral in ltrates, and sputum cultures are negative for bacteria. Mortality is high and autopsy reveals necrotising bronchitis, hyaline membranes, intra-alveolar haemorrhage and oedema, and interstitial in ammation.

Bacterial pneumonia as a complication of in uenza infection was rst documented during the 1918 pandemic as a biphasic illness in which typical in uenza symptoms occur and then resolve, followed 4–14 days later with a recurrence of fever associated with dyspnoea, productive cough, and consolidation on chest imaging.[43,47] The most common organisms isolated from sputum are *Streptococcus pneumoniae*, *Staphylococcus aureus* (including community-acquired meticillin-resistant *S aureus*), *Haemophilus in uenzae*, other *Streptococcus* species, and other Gram-negative rods.[12,43,47] A large proportion of fatalities during the 2009 pandemic was associated with bacterial pneumonia.[48,49] Combinations of primary in uenza-associated pneumonia and secondary bacterial pneumonia can occur.

In uenza infection is associated with bronchiolitis and croup.[12,21,43] The infection can lead to exacerbations of underlying chronic lung disease such as asthma, chronic obstructive pulmonary disease, and chronic bronchitis, and a decline in lung function in individuals with cystic brosis.

Non-pulmonary complications

In addition to pulmonary complications, several e ects on other organ systems can be seen in in uenza.[1,12,21,43,47,50] Myositis and rhabdomyolysis occur rarely, with varying severity. Di culties with ambulation and renal failure can occur and can persist for 4–6 weeks. Cardiac complications of in uenza include myocarditis, pericarditis, and exacerbation of underlying cardiac disease. In uenza has also been associated with neurological manifestations, including Reyes syndrome, encephalomyelitis, transverse myelitis, Guillain-Barré syndrome, aseptic meningitis, and encephalitis. Reyes syndrome is characterised by acute encephalopathy without evidence of in ammation on analysis of cerebrospinal uid, associated with liver

	Sensitivity	Turnaround time	Advantages	Disadvantages
Viral culture	Close to 100%	3–10 days	High sensitivity and specificity; virus available for characterisation (recovery of new and divergent strains); ability to recover other viruses	Poor specimen quality might affect yield; results not available in time to inform clinical decision making; time and labour intensive; specialised laboratory facilities required
Rapid viral culture*	70–90%	1–3 days	Faster than traditional viral culture; less expertise needed than for traditional cell culture	Less sensitive than traditional viral culture; might miss divergent influenza viruses; specialised laboratory facilities required
Rapid antigen detection: direct fluorescent antibody	70–90%	1–4 h	Rapid turnaround; can identify additional pathogens (different staining methods); can assess sample quality	Sensitivity and specificity dependent on expertise of technician; specialised equipment required; virus is not available for characterisation of antigenicity
Rapid antigen detection: immunochromatogenic assay	59–93%	<30 min	No specialised equipment or technical skill required; specialised specimen transport not required; rapid results	Least sensitive method; virus is not available for characterisation of antigenicity
RT-PCR	Close to 100%	1–8 h	High sensitivity and specificity; specimen quality and handling have less impact on sensitivity; typing, subtyping, and sequencing possible; can be combined with multiplex technology	Expensive; specialised equipment and trained personnel required; potential for cross-contamination; might miss divergent strains (dependent on primers)

*This technique is a modification of conventional viral culture, where the clinical specimen is inoculated onto a cell monolayer and centrifuged before incubation. Specimens are then stained and examined by immunofluorescence.

Table 1: **Comparison of methods for diagnostic testing of influenza**[1,21,40,51,59]

function abnormalities and elevated serum ammonia concentrations. This syndrome occurred mostly in children receiving aspirin and is now a rare event because aspirin use in children has declined substantially.

Diagnosis

Clinical diagnosis of influenza is difficult because symptoms range in severity and overlap with those caused by other respiratory viruses.[51] The sensitivity and specificity of clinical diagnosis are influenced by the case definition used, the characteristics of the host, and the prevalence of influenza in the community.[52–56] In healthy adults, the sensitivity of clinical diagnosis ranges from 29% to 80%.[52–55] Clinicians are likely to appropriately diagnose influenza infection when fever and cough are part of the case definition, when influenza rates are high in the community, and when patients are severely ill or are at an increased risk of developing complications. Laboratory tests are available to aid in the diagnosis and can be used to guide treatment decisions, avoid inappropriate use of antibiotics, and provide information for influenza surveillance.[1,40,57–60] Physicians should be aware of influenza rates in the community and use laboratory tests when the results will influence clinical management.

Influenza testing should be done early in the course of the illness, when viral shedding is at its peak.[51,59] The preferred samples include nasopharyngeal swabs, nasal washes, and nasopharyngeal aspirates. Lower respiratory tract samples such as bronchoalveolar lavage and endotracheal aspirates can also be tested and might be more sensitive in individuals with influenza-associated pneumonia.[61] Recommended diagnostic methods include viral culture, antigen detection, and nucleic acid testing.[1,40,57–60] The sensitivities and advantages of these modalities are summarised in table 1. Serological testing for influenza to aid in clinical decision making is not recommended, but it can be useful in clinical studies and outbreak investigations.[40,51]

Licensed therapeutics

Four classes of antiviral drugs are approved for the treatment of influenza in several countries: adamantanes, neuraminidase inhibitors, membrane fusion inhibitors, and RNA-dependent RNA polymerase inhibitors.[62] Of these, only the adamantane derivatives and neuraminidase inhibitors are licensed for use in the European Union and the USA.[40] The adamantane derivatives include two oral agents, amantadine and rimantadine, which inhibit the matrix 2 ion channel of influenza A, but not B, viruses.[1] Point mutations in the membrane spanning region of the matrix 2 protein confer resistance to both amantadine and rimantadine while preserving viral fitness.[63] All currently circulating seasonal influenza viruses are resistant to the adamantane derivatives and so the use of these agents is not recommended.[10,40]

Neuraminidase inhibitors inhibit the function of the influenza virus neuraminidase.[1] During the 2015–16 influenza season, oral oseltamivir and inhaled zanamivir were recommended for use in the European Union and the USA.[10,40] Intravenous peramivir is also recommended for use in the USA, and intravenous zanamivir is available for severely ill patients with suspected

Route	Treatment dose	Prophylactic dose	Special population considerations
Oseltamivir (Tamiflu; Roche)	Oral		
	Adults: 75 mg twice daily for 5 days Children (2 weeks and older): weight-based dosing twice a day for 5 days	Adults: 75 mg once daily for 7–10 days Children (3 months and older): weight-based dosing once a day for 7–10 days	Available in the USA and European Union; dose adjusted in renal failure; drug of choice in pregnancy; drug of choice in patients with severe infection or patients admitted to hospital; side-effects include nausea or vomiting, rare and serious skin reactions, and neuropsychiatric effects (observed in post-marketing studies in Japan)
Zanamivir (Relenza; GlaxoSmithKline)	Inhaled		
	7 years and older: 10 mg twice daily for 5 days	5 years and older: 10 mg once daily for 7–10 days	Available in the USA and European Union (except for Cyprus); contraindicated in patients with underlying lung disease; contraindicated in intubated patients (ventilator blockage)
Peramivir (Rapivab; BioCryst Pharmaceuticals)	Intravenous		
	18 years and older: 600 mg in a single dose	NA	Available in the USA; dose adjusted in renal failure; given for at least 5 days if used to treat patients in hospital

NA=not applicable.

Table : Treatment options for influenza infections in the USA and Europe[40,61]

oseltamivir-resistant influenza on a compassionate basis by emergency investigational drug request.[41] Table 2 describes recommended options for antivirals in the European Union and the USA. Prophylaxis is recommended in unvaccinated individuals at high risk of developing complications after exposure to influenza virus (eg, after close contact with infected individuals) and for control of outbreaks in an institutional setting (in an institutional outbreak, the antiviral agent should be continued for at least 2 weeks or 7 days after the last documented infection occurs).[40] Treatment of influenza infection is indicated for patients admitted to hospital with suspected or confirmed influenza and individuals at high risk of developing influenza-related complications. Treatment can also be considered for uncomplicated influenza infections in low-risk individuals who present within 48 h of symptom onset.[40]

Resistance to neuraminidase inhibitors can occur through multiple mechanisms.[65] Some resistance-conferring mutations change the catalytic framework of the neuraminidase molecule or lead to internal deletions in the neuraminidase so that the drug cannot bind, whereas others alter the haemagglutinin so that neuraminidase activity is not required to release the virus from the infected cell.[66,67] These mutations confer variable changes in viral fitness and could yield resistance to one or more of the available neuraminidase inhibitors. During the 2007–08 influenza season, substantial resistance to oseltamivir emerged in influenza A H1N1 viruses through a histidine to tyrosine substitution (H275Y) in the neuraminidase protein.[66] Since the emergence of H1N1pdm09 influenza A viruses and their establishment as circulating epidemic strains, resistance to neuraminidase inhibitors has been uncommon.[68] As of March, 2016, all circulating influenza A H3N2 and influenza B isolates in the USA were susceptible to the licensed neuraminidase inhibitors and only 5% of influenza A H1N1pdm09 isolates were resistant to oseltamivir and peramivir.[40] Rates of oseltamivir resistance were lower than 5% in the European Union, with resistance observed in less than 1% of influenza A H1N1pdm09 isolates.[40]

Controversies in therapeutics

Although neuraminidase inhibitors are widely used, the effectiveness of these agents has been the subject of much debate. All three licensed neuraminidase inhibitors are most effective when given early in infection, preferably within 48 h of onset of illness.[40] In randomised controlled trials of uncomplicated influenza in healthy outpatients, neuraminidase inhibitors shortened the duration of clinical symptoms by less than 1 day.[69,72]

Data on the effectiveness of neuraminidase inhibitors in the prevention of influenza-related complications are variable. A 2014 Cochrane review[71] found no decrease in the risk of hospital admissions (risk difference [RD] 0·15%; 95% CI –0·78 to 0·91) or serious complications with oseltamivir treatment (0·07%; –0·78 to 0·44). Data analysis was done in an intention-to-treat (ITT) group without accounting for the results of influenza testing. A subsequent meta-analysis, by Dobson and colleagues,[69] divided individuals into an ITT group and an ITT infected (ITTI) group, in which influenza infection was confirmed by testing. This study estimated a 44% risk reduction (relative risk 0·56 [95% CI 0·42–0·75]; p=0·0001) in lower respiratory tract complications and a 63% risk reduction (0·37 [0·17–0·81]; p=0·013) in hospital stay for the ITTI group that received oseltamivir.[69]

The 2014 Cochrane review[71] found that prophylaxis with oseltamivir or zanamivir had a modest effect on prevention of symptomatic influenza illness in individuals (RD 3·05% [95% CI 1·83–3·88] for oseltamivir; 1·98% [0·98–2·54] for zanamivir) and a slightly better effect in households (13·6% [9·52–15·47] for oseltamivir; 14·8% [12·18–16·55] for zanamivir).[70,72] Additional studies, showing that prophylaxis can reduce household transmission of influenza, lend support to the use of these agents in a pandemic setting, although large, community-based studies have not been done.[73,74]

	Mechanism of action	Route of administration	Licence or investigational status
Licensed antiviral agents			
Laninamivir	Neuraminidase inhibitor	Inhaled	Licensed in Japan for seasonal in uenza
Arbidol	Interaction with haemagglutinin to prevent membrane fusion	Oral	Licensed in Russia and China for seasonal in uenza
Favipiravir (T-705)	Inhibition of viral RNA-dependent RNA polymerase	Oral	Licensed in Japan for pandemic in uenza
Investigational antiviral agents			
Monoclonal antibodies (anti-haemagglutinin head, anti-haemagglutinin stem, anti-M2e)	Neutralisation of virus; antibody e ector function; stimulation of immune response	Intravenous	Preclinical; clinical trials
Nitazoxanide	Interferon induction; inhibitor of haemagglutinin maturation	Oral	Approved for parasitic infections; preclinical; clinical trials
DAS181	Sialidase	Inhaled	Preclinical; clinical trials
Â " # "	Inhibition of polymerase basic protein 2 (PB2)	Oral	Preclinical; clinical trials
Â "	Small interfering RNA construct	Intravenous	Preclinical; clinical trials

Table : Antivirals licensed for in uenza treatment outside Europe and USA, and investigational antiviral agents[31,88,89]

Many countries recommend oral oseltamivir for treatment of complicated in uenza, primarily on the basis of observational data, which suggest a mortality bene t in patients treated with oseltamivir.[10,49,41,75–77] A meta-analysis[76] of individual patient data for 2234 in uenza-infected individuals admitted to hospital between January, 2009, and March, 2011, reported a lower risk of mortality in individuals treated with a neuraminidase inhibitor than in untreated individuals (adjusted odds ratio 0·81; 95% CI 0·70–0·95; p=0·0024). Earlier treatment was associated with better outcomes than later initiation of therapy. In other observational studies, treatment delayed by more than 48 h after symptom onset, increased durations of therapy, and higher doses of oseltamivir have been used in severely ill patients, but e cacy data are not available.[10,76,78–80]

Taken together, these data support the use of neuraminidase inhibitors for prophylaxis against in uenza infections in both individual patients and outbreak settings. When used for treatment, neuraminidase inhibitors provide a slight bene t in healthy adults, shortening the duration of illness by approximately 1 day. Additional data are needed to better assess the use of neuraminidase inhibitors in high-risk or severely ill patients, but in the setting of limited treatment options and acceptable side-e ect pro les these agents are widely used.

Research on therapeutics

Controversial e cacy data and the potential for drug resistance make adjuncts to current treatment, as well as the development of novel therapeutics, important areas of research. Combinations of antiviral agents have an additive treatment bene t in preclinical studies.[81] A triple combination of amantadine, ribavirin, and oseltamivir showed synergistic activity, in vitro, against both adamantane-sensitive and adamantane-resistant viruses. In a retrospective observational study of critically ill adults infected with H1N1pdm09 virus, this regimen did not show a signi cant decrease in 14-day mortality (17% vs 35%; p=0.08) and 90-day mortality (46% vs 59%; p=0·23) compared with oseltamivir treatment alone.[81] Several low-cost, widely available immunomodulatory agents, including statins and macrolides, have been used in animal models and human beings as adjuncts to neuraminidase inhibitors for in uenza treatment, with variable results.[81–84] Corticosteroids have also been used as adjuncts to antivirals, particularly in critically ill patients.[81,85,86] Data are scarce, but observational studies from the 2009 in uenza pandemic suggest the frequency of secondary infections, duration of intensive care unit stays, and mortality are all increased in patients treated with corticosteroids. Several antiviral agents are licensed for in uenza treatment outside the European Union and USA (table 3). Additionally, various promising antiviral drugs with novel mechanisms of anti-in uenza activity have shown e cacy in animal models or initial clinical studies (table 3).[31,82,87–92]

Vaccination

The most e ective method for prevention and control of in uenza infection is vaccination.[1,22,93] Licensed seasonal vaccines are updated annually and WHO makes recommendations on the composition of the next season's in uenza vaccines on the basis of surveillance, laboratory, and clinical observations.[93] This process occurs twice a year, in February for the northern hemisphere and in September for the southern hemisphere. Tropical countries follow one of these recommendations. Procuring the in uenza vaccine can be di cult for people planning to travel to the opposite hemisphere during the local in uenza season.

Table 4 summarises the vaccines that are currently recommended for seasonal use in the USA. Vaccine availability varies by country in the European Union. Three classes of licensed in uenza vaccines are available: inactivated virus, live attenuated virus, and recombinant haemagglutinin vaccines.[10,93,94] Available

	Quadrivalent vs trivalent*	Route	Approved age group	Comments
Inactivated	Quadrivalent or trivalent	Intramuscular	≥6 months	Contains 15 g of each haemagglutinin
Inactivated: intradermal	Quadrivalent	Intradermal	18–64 years	Contains 9 g of each haemagglutinin
Inactivated: derived from cell culture	Trivalent	Intramuscular	≥18 years	Contains 15 g of each haemagglutinin; contains egg protein; manufacturing does not rely on eggs
Inactivated: high dose	Trivalent	Intramuscular	≥65 years	Contains 60 g of each haemagglutinin
Live attenuated†	Quadrivalent	Intranasal	2–49 years	Cold adapted; uses a master donor virus plus the haemagglutinin and neuraminidase of the circulating viruses; generates a broader immune response (T-cell, mucosal); not approved for use in immunocompromised patients or pregnant women
Recombinant	Trivalent	Intramuscular	≥18 years	Made with recombinant DNA technology to produce full-length haemagglutinin; shorter manufacturing time than for egg-derived or cell-culture-derived vaccines; can be used in individuals with egg allergy

*Trivalent vaccines contain antigens from the circulating H1N1 and H3N2 in uenza A viruses and the dominant in uenza B virus circulating at the time of vaccine strain selection. Quadrivalent vaccines contain antigens from the circulating H1N1 and H3N2 in uenza A viruses and both lineages of in uenza B. †Live attenuated vaccine not recommended by the US Advisory Committee on Immunization Practices for the 2016–17 season; this table represents the 2015–16 in uenza season.

Table : Types of in uenza vaccine licensed for use in the USA 2015–16 in uenza season[28,93,98]

vaccines contain antigens from the in uenza A H1N1 and H3N2 subtypes, along with the dominant circulating lineage of in uenza B (trivalent vaccines) or both lineages of in uenza B (quadrivalent vaccines). Previously, the use of live attenuated in uenza vaccines was recommended in young children in the USA on the basis of favourable clinical trial results and observational data in this age range.[95,98] In 2016, Gaglani and colleagues[99] analysed data from the US Flu Vaccine E ectiveness Network for the 2013–14 in uenza season in fully vaccinated children aged 2–17 years, and showed that for in uenza A H1N1pdm09 the live attenuated vaccine provided inferior protection (e ectiveness 17%; 95% CI –39 to 51) to that of the inactivated vaccine (60%; 36 to 74). This nding and similar e ectiveness data during the 2015–16 in uenza season led the US Advisory Committee on Immunization Practices to recommend that live attenuated vaccines are not used in the 2016–17 in uenza season.[40] By contrast, European data have continued to show protection with live attenuated vaccines in children, although e ectiveness against in uenza A H1N1pdm09 is lower than against in uenza B.[100] The live attenuated vaccine continues to be recommended in many European countries, and further investigation is needed to optimise vaccination strategies.

The ability of vaccines to protect a target population is assessed in vaccine e cacy and e ectiveness studies.[101] Vaccine e cacy refers to the speci c reduction in the rates of laboratory-con rmed in uenza and is assessed in randomised controlled trials. Vaccine e ectiveness is determined by observational data and assesses other endpoints besides laboratory-con rmed in uenza, including in uenza-like illness, medically attended respiratory illness, the burden of missed work, and hospital admissions, during the in uenza season.[10] Vaccine e ectiveness studies now use a test-negative design in which individuals who present to health-care settings with an in uenza-like illness and test positive for in uenza are assessed for vaccination status.[102] These studies have shown that in uenza vaccination is most e ective when the vaccine strain matches the circulating epidemic strain.[93] E ectiveness rates of 50–60% are reported for well matched in uenza vaccines in healthy adults and children.[40,102,103] Vaccine bene t is greatest among high-risk groups such as individuals older than 65 years (especially those with comorbidities), immunocompromised patients, and young children.[104–107] In the 2013–14 in uenza season, the CDC estimated that in uenza vaccination led to 90 068 (95% CI 52 231–148 471) fewer overall hospital admissions than if no vaccination had taken place.[107] When seasonal in uenza viruses undergo antigenic drift after a vaccine has been distributed, a marked decrease in vaccine e ectiveness occurs.[40] Vaccine e ectiveness may also be in uenced by previous vaccination. Some studies have suggested that annual vaccination could result in decreased vaccine e ectiveness,[108,109] but additional data are needed to investigate this issue and its implications for vaccine policy.

In Europe, recommendations for routine annual in uenza vaccination and rates of vaccination coverage further vary by country.[10] Most countries recommend in uenza vaccination in individuals at high risk of developing complications, including elderly people, pregnant women, individuals with medical comorbidities, residents of long-term care facilities, and health-care workers. In the USA, annual in uenza vaccination is recommended for all individuals aged 6 months or older and is particularly emphasised for individuals at high risk of developing complications of in uenza infection, and for health-care workers.[84] However, the CDC estimated that in the 2014–15 in uenza season only 47% of children and adults were vaccinated, with the lowest rates (33%) seen in healthy adults aged 18–49 years.[40] Higher rates were seen in adults older than 65 years

(67%), adults aged 18–64 years with high-risk conditions (48%), pregnant women (50%), and children aged 6 months to 17 years (59%). 77% of health-care personnel were vaccinated, but rates as low as 64% were reported among health-care personnel in long-term care facilities.[26]

Only 40–50% of pregnant women in the USA were vaccinated during the 2014–15 in uenza season.[110] Maternal vaccination is the primary mechanism to protect young infants because vaccines are not licensed for infants younger than 6 months.[111] However, pregnant women frequently defer vaccination because of concerns regarding the safety of the in uenza vaccine during pregnancy. Several reviews have shown no increase in adverse maternal or fetal e ects after administration of inactivated seasonal in uenza or H1N1pdm09 in uenza vaccines.[112–114] Pregnant women should therefore be informed of the bene ts of vaccination for themselves and their infants, and should be reassured of the safety of inactivated in uenza vaccines.

Antigenic drift of seasonal in uenza viruses and the emergence of novel in uenza viruses by antigenic shift, combined with the time required to develop an in uenza vaccine, make new vaccine approaches an important component of in uenza research. New approaches such as DNA-based vaccines, viral vectors, virus-like particles, cell-culture techniques, recombinant DNA, novel live attenuated vaccines, and adjuvants are being studied to improve vaccine development and immunogenicity.[115] Oil-in-water adjuvants, such as MF59 and AS03, improve immune responses to inactivated in uenza vaccines, particularly in young children (aged 6 months and older) and people older than 60 years.[116,117] Several such vaccines have been licensed in Europe for seasonal in uenza and in the USA for individuals at high risk of exposure in the event of an H5N1 pandemic. Generally, oil-in-water adjuvants are well tolerated with a side-e ect pro le similar to that of non-adjuvanted inactivated vaccines.[117] However, results of retrospective studies[118,119] in Europe suggested an association between Pandemrix (GlaxoSmithKline), an AS03-adjuvanted H1N1pdm09 vaccine, and the subsequent development of narcolepsy in vaccinated individuals younger than 21 years. The role of the AS03 adjuvant in this association is unclear, and other factors—including a particular HLA type—might have a role.[117] A universal in uenza vaccine that is broadly cross-protective could replace annual seasonal in uenza vaccination and provide protection following the emergence of a novel in uenza virus.[93,120,121] Vaccines based on various viral targets, such as the haemagglutinin stem, matrix 2 protein, and consensus sequences of the haemagglutinin head, are in development.[93,115]

Ecology

In uenza A viruses have been isolated from several species besides human beings, including birds, pigs, dogs, cats, horses, and marine mammals.[122] Waterfowl and shorebirds are the natural reservoir of in uenza A viruses and the source of all strains that infect domestic avian species and mammals.[2]

In waterfowl, in uenza infection causes localised respiratory or gastrointestinal infection without overt clinical manifestations.[2] In uenza A viruses replicate predominantly in the intestinal tract of waterfowl and are spread through faecal contamination of water.[122] Transmission of in uenza A viruses from wild birds to domestic poultry occurs on farms or in rice paddies along migratory bird yways, in backyard poultry farms, and in live bird markets where multiple avian species are in close proximity. Domestic poultry are not natural hosts for in uenza viruses and have a range of clinical manifestations, from asymptomatic infection or decreased egg production to severe multisystem disease and rapid death.[2] Severe disease in poultry is linked to the properties of the viral haemagglutinin.[24,122] Low pathogenicity avian in uenza viruses have haemagglutinin molecules that can only be cleaved by proteases in the gastrointestinal tract of waterfowl, whereas highly pathogenic avian in uenza viruses of the H5 and H7 subtypes have molecular motifs that allow the haemagglutinin of these viruses to be cleaved by proteases outside the gastrointestinal tract, resulting in disseminated multisystem infection. Both high pathogenicity and low pathogenicity avian in uenza viruses can cause severe disease in human beings.[123]

Interspecies transmission of in uenza A viruses is a complicated process that is restricted by both viral and host factors. The receptor speci city of the haemagglutinin protein binding to sialyloligosaccharides on the host cell is an important determinant of the host range of in uenza A viruses.[2] Aminoacid changes in the haemagglutinin receptor binding domain can facilitate interspecies transmission. The viral polymerase genes have also been implicated in host-range restriction and virulence.[24] The replication e ciency of an in uenza virus corresponds to its virulence.[123] Certain aminoacid substitutions in the polymerase proteins can enhance the pathogenicity of in uenza viruses.[124] The best-described aminoacid change is a glutamic acid to lysine substitution at position 627 in polymerase basic protein 2 (PB2). Most avian in uenza viruses have a glutamic acid at this position, whereas most human viruses have a lysine.[125] Several other viral and host factors have been implicated in interspecies transmission of in uenza A viruses, and research is ongoing to further delineate the mechanisms involved in this complex process.

Emerging pandemic threats

H5N1

In 1997, a 3-year-old boy in Hong Kong developed a respiratory illness and died of acute respiratory distress syndrome.[126] An in uenza virus isolated from this patient was composed entirely of avian in uenza virus genes and constituted the rst detection of H5N1 avian in uenza A infection in human beings. According to WHO, 856 cases

and 452 deaths have occurred from avian in uenza A H5N1 infection in 16 countries as of Oct 3, 2016, with the largest number of cases in Indonesia, Vietnam, and Egypt.[41,120] Human cases of avian in uenza A H5N1 infection are typically associated with exposure to infected poultry while butchering, defeathering, and preparing sick birds for consumption, or associated with live bird markets.[127] Isolated person-to-person transmission of H5N1 in close contacts has been reported, but sustained transmission has not occurred.[40] H5N1 infection in human beings begins after an incubation period of 2–5 days, with rapid progression of the disease.[128] Respiratory failure and multi-organ dysfunction are common, and case-fatality rates reach as high as 60%.[129] Over 90% of reported cases are in individuals younger than 40 years of age. The prevalence of asymptomatic or mild infection is unknown, but seroprevalence studies have documented H5N1-speci c antibodies in a minority of individuals with high-risk exposures.[128,130] Extensive adamantane resistance has been documented in H5N1 in uenza strains, but most strains remain susceptible to neuraminidase inhibitors.[129] Early administration of oseltamivir in H5N1 infection is recommended, but data to support this action are mostly observational and case-fatality rates are high despite oseltamivir use. Avian H5N1, H5N2, and H5N8 viruses have been detected in birds in the USA and avian H5N8 viruses have been detected in birds in Europe, but human cases have not been reported despite documented exposure.[49]

H7N9

Before 2013, with the exception of one fatal case, sporadic cases of infection with H7 subtype viruses (H7N7, H7N3, and H7N2) were associated with mild illness.[131] In 2013, a novel H7N9 virus emerged in China and has reappeared annually, resulting in 798 reported cases and 320 deaths as of Oct 3, 2016.[41,132] Most human cases of avian in uenza A H7N9 are associated with exposure to poultry, although rare cases of person-to-person transmission have been reported.[131,133] The H7N9 virus often circulates undetected in poultry, since it is a low pathogenicity avian in uenza virus.[120] Thus, infections in human beings occur without any warning unless in uenza surveillance is done among local poultry. Human H7N9 infection causes a severe respiratory illness.[134] As with seasonal in uenza, infection is most severe in elderly people and in individuals with comorbidities. A faster overall increase has been observed in the number of human cases of H7N9 compared with H5N1 virus infections.[41,134] The H7N9 virus shows extensive resistance to the adamantanes, but most strains are susceptible to oseltamivir.[135] Although e cacy data are scarce, oseltamivir is recommended for treatment of H7N9 infection.

Other in uenza subtypes

In addition to the subtypes discussed above, human infections with other avian and swine in uenza A viruses have been documented, including H9N2, H10N8, H10N7, and H6N1.[2,120,131] Most infections are characterised by mild respiratory illness or conjunctivitis, but H10N8 infection was associated with cases of severe pneumonia in China.[120] H9N2 viruses are of particular interest because they are the source of the internal protein genes of the H7N9, H6N1, and H10N8 viruses in China. H9N2 viruses in Asian poultry have also shown receptor speci city similar to that of human in uenza viruses, although to date only 15 human infections with H9N2 in uenza A virus have been documented, with no evidence of person-to-person transmission.[121,136,137]

In uenza viruses cause seasonal epidemics in pigs.[138] Circulating viruses in the US swine population include H1N1, H3N2, and H1N2 subtypes. Because both 2,6-linked and 2,3-linked sialyloligosaccharide receptors are found in the porcine respiratory tract, both avian and human in uenza A viruses can cause illness in pigs.[122] Seasonal human in uenza viruses are commonly transmitted and established in pigs.[138] These viruses have the capacity to reassort within the swine population, and such events are thought to have generated the H1N1pdm09 in uenza A virus. Sporadic transmission of swine in uenza A viruses to human beings can also occur.[131] These viruses are called variant viruses and are denoted by adding the letter “v” to the end of the virus subtype. Human infections with H1N1v, H3N2v, and H1N2v viruses have occurred in the USA.[4] H3N2v infections account for the majority of reported cases and have caused 391 illnesses since they were rst detected in August, 2011. Cases are generally reported in individuals who have had close contact with pigs either through occupational exposure or at agricultural fairs.[139] Some degree of person-to-person transmission has been documented.[139] Most in uenza variant virus infections have occurred in children, presumably because the prevalence of cross-reactive antibodies increases with age.[40] The illness is generally mild and is similar to uncomplicated seasonal in uenza.

In summary, animal in uenza viruses can directly infect human beings and, as with human in uenza viruses, the resulting clinical illness can range from mild to severe. A history of exposure to sick birds or travel to countries where cases of avian in uenza are occurring might raise suspicion of a novel in uenza virus infection, but a de nitive diagnosis requires laboratory tests that are usually only available through public health reference laboratories. Identi cation of such infections is important for determining the source of the virus, evidence of person-to-person spread, and assessment of pandemic potential.

Contributors

CP and KS contributed equally to the design, writing, and review of this Seminar.

Declaration of interests

KS has a patent issued for pandemic in uenza vaccines, and was the principal investigator on a cooperative research and development agreement with MedImmune to generate and evaluate pandemic

influenza vaccines. Neither KS nor her laboratory received financial support from MedImmune. CP declares no competing interests.

Acknowledgments

Our research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. We thank Tara Palmore and Catherine Luke for their critical review of the manuscript. We also thank Diane Cooper for her assistance with the literature search. Additional references that could be of interest to readers are included in the appendix. Work on this paper was done while KS was at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. KS is now at the WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia (Kanta.subbarao@influenzacentre.org).

References

1 Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practices of infectious diseases, 8th edn. Philadelphia, PA: Elsevier, 2015.

2 Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. *Annu Rev Med* 2000; **51:** 407–21.

3 Yang L, Chan KH, Suen LK, et al. Age-specific epidemic waves of influenza and respiratory syncytial virus in a subtropical city. *Sci Rep* 2015; **5:** 10390.

4 Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. *Arch Intern Med* 1982; **142:** 85–89.

5 Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC Infect Dis* 2014; **14:** 480.

6 Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. *BMC Infect Dis* 2014; **14:** 670.

7 Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA* 2004; **292:** 1333–40.

8 Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. *Vaccine* 2007; **25:** 5086–96.

9 Lafond KE, Nair H, Rasooly MH, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: a systematic analysis. *PLoS Med* 2016; **13:** e1001977.

10 European Centre for Disease Prevention and Control. Influenza. 2016. http://ecdc.europa.eu/en/healthtopics/influenza/Pages/home.aspx (accessed June 3, 2016).

11 Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. *MMWR Morb Mortal Wkly Rep* 2010; **59:** 1057–62.

12 Cox NJ, Subbarao K. Influenza. *Lancet* 1999; **354:** 1277–82.

13 Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. *Clin Infect Dis* 2014; **58:** 214–24.

14 Greenbaum A, Chaves SS, Perez A, et al. Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012. *Infection* 2014; **42:** 165–70.

15 Horby P, Nguyen NY, Dunstan SJ, Baillie JK. An updated systematic review of the role of host genetics in susceptibility to influenza. *Influenza Other Respir Viruses* 2013; **7** (suppl 2)**:** 37–41.

16 Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med* 2000; **342:** 232–39.

17 Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. *Acta Obstet Gynecol Scand* 2015; **94:** 797–819.

18 Schuurmans MM, Isenring BD, Jungo C, et al. Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study. *Transpl Infect Dis* 2014; **16:** 430–39.

19 Xuan Y, Wang LN, Li W, et al. IFITM3 rs12252 T>C polymorphism is associated with the risk of severe influenza: a meta-analysis. *Epidemiol Infect* 2015; **143:** 2975–84.

20 Van Kerkhove MD, Mumford E, Mounts AW, et al. Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review. *PLoS One* 2011; **6:** e14582.

21 Long SS, Pickering LK, Prober CG, eds. Principles and practice of pediatric infectious diseases, 4th edn. China: Elsevier, 2012.

22 Shaw ML, Palese P. Orthomyxoviridae. In: Knipe DM, Howley, PM, eds. Fields virology, 6th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2013: 1151–84.

23 Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. *PLoS Pathog* 2013; **9:** e1003657.

24 Kash JC, Taubenberger JK. The role of viral, host, and secondary bacterial factors in influenza pathogenesis. *Am J Pathol* 2015; **185:** 1528–36.

25 Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. *Nature* 2006; **440:** 435–36.

26 Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. *Virus Res* 2011; **162:** 19–30.

27 Killingley B, Nguyen-Van-Tam J. Routes of influenza transmission. *Influenza Other Respir Viruses* 2013; **7** (suppl 2)**:** 42–51.

28 Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. *JAMA* 2009; **302:** 1865–71.

29 Nikitin N, Petrova E, Trifonova E, Karpova O. Influenza virus aerosols in the air and their infectiousness. *Adv Virol* 2014; **2014:** 859090.

30 Tellier R. Review of aerosol transmission of influenza A virus. *Emerg Infect Dis* 2006; **12:** 1657–62.

31 Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. *Lancet Infect Dis* 2007; **7:** 257–65.

32 Gustin KM, Belser JA, Wadford DA, et al. Influenza virus aerosol exposure and analytical system for ferrets. *Proc Natl Acad Sci USA* 2011; **108:** 8432–37.

33 Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. *Proc Soc Exp Biol Med* 1966; **122:** 800–04.

34 Leung NH, Zhou J, Chu DK, et al. Quantification of influenza virus RNA in aerosols in patient rooms. *PLoS One* 2016; **11:** e0148669.

35 Lindsley WG, Noti JD, Blachere FM, et al. Viable influenza A virus in airborne particles from human coughs. *J Occup Environ Hyg* 2015; **12:** 107–13.

36 Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza aboard a commercial airliner. *Am J Epidemiol* 1979; **110:** 1–6.

37 Wong BC, Lee N, Li Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. *Clin Infect Dis* 2010; **51:** 1176–83.

38 Cowling BJ, Ip DK, Fang VJ, et al. Aerosol transmission is an important mode of influenza A virus spread. *Nat Commun* 2013; **4:** 1935.

39 Riley RL. Airborne infection. *Am J Med* 1974; **57:** 466–75.

40 Centers for Disease Control and Prevention. Influenza (flu). 2016. http://www.cdc.gov/flu/ (accessed Nov 16, 2016).

41 WHO. Influenza. 2016. http://www.who.int/topics/influenza/en/ (accessed Nov 16, 2016).

42 Bin-Reza F, Lopez Chavarrias V, Nicoll A, Chamberland ME. The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. *Influenza Other Respir Viruses* 2012; **6:** 257–67.

43 Nicholson KG. Clinical features of influenza. *Semin Respir Infect* 1992; **7:** 26–37.

44 Ip DK, Lau LL, Chan KH, et al. The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections. *Clin Infect Dis* 2016; **62:** 431–37.

45 Esposito S, Daleno C, Baldanti F, et al. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. *Virol J* 2011; **8:** 349.

46 Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am J Epidemiol* 2008; **167:** 775–85.

47 Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. *Am J Med* 2008; **121:** 258–64.

48 Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. *Arch Pathol Lab Med* 2010; **134:** 235–43.

49 Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. *Am J Pathol* 2010; **177:** 166–75.

50 Mistry RD, Fischer JB, Prasad PA, Coffin SE, Alpern ER. Severe complications in influenza-like illnesses. *Pediatrics* 2014; **134:** e684–90.

51 Dwyer DE, Smith DW, Catton MG, Barr IG. Laboratory diagnosis of human seasonal and pandemic influenza virus infection. *Med J Aust* 2006; **185** (suppl 10): 48–53.

52 Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. *Clin Infect Dis* 2000; **31:** 1166–69.

53 Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? *JAMA* 2005; **293:** 987–97.

54 Miller MR, Peters TR, Suerken CK, Snively BM, Poehling KA. Predictors of influenza diagnosis among patients with laboratory-confirmed influenza. *J Infect Dis* 2015; **212:** 1604–12.

55 Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. *Arch Intern Med* 2000; **160:** 3243–47.

56 Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children. *Clin Infect Dis* 2005; **41:** 1198–200.

57 Bouscambert M, Valette M, Lina B. Rapid bedside tests for diagnosis, management, and prevention of nosocomial influenza. *J Hosp Infect* 2015; **89:** 314–18.

58 Kim DK, Poudel B. Tools to detect influenza virus. *Yonsei Med J* 2013; **54:** 560–66.

59 Peaper DR, Landry ML. Rapid diagnosis of influenza: state of the art. *Clin Lab Med* 2014; **34:** 365–85.

60 Petrozzino JJ, Smith C, Atkinson MJ. Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis. *J Emerg Med* 2010; **39:** 476–90.e1.

61 Ohkura N, Tani M, Nishitsuji M, Nishi K. Primary A (H1N1) pdm09 influenza pneumonia diagnosed on reverse transcription-polymerase chain reaction (RT-PCR) of bronchoalveolar lavage fluid but not rapid tests with nasopharyngeal swabs. *Intern Med* 2015; **54:** 1441–45.

62 Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence. *Expert Rev Anti Infect Ther* 2015; **13:** 417–25.

63 Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. *Curr Top Microbiol Immunol* 1992; **176:** 119–30.

64 Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2015–2016. *Pediatrics* 2015; **136:** 792–808.

65 Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. *Antiviral Res* 2008; **78:** 91–102.

66 Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. *Antiviral Res* 2014; **110:** 31–41.

67 Gulati S, Smith DF, Air GM. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. *Virol J* 2009; **6:** 22.

68 Takashita E, Kiso M, Fujisaki S, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. *Antimicrob Agents Chemother* 2015; **59:** 2607–17.

69 Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet* 2015; **385:** 1729–37.

70 Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014; **348:** g2545.

71 Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2014; **4:** CD008965.

72 Jones M, Jefferson T, Doshi P, Del Mar C, Heneghan C, Onakpoya I. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Clin Microbiol Infect* 2015; **21:** 217–21.

73 Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. *PLoS One* 2014; **9:** e113633.

74 Fry AM, Goswami D, Nahar K, et al. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial. *Lancet Infect Dis* 2015; **15:** 654–62.

75 Nguyen-Van-Tam JS, Openshaw PJM, Nicholson KG. Antivirals for influenza: where now for clinical practice and pandemic preparedness? *Lancet* 2014; **384:** 386–87.

76 Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir Med* 2014; **2:** 395–404.

77 Chaves SS, Perez A, Miller L, et al. Impact of prompt influenza antiviral treatment on extended care needs after influenza hospitalization among community-dwelling older adults. *Clin Infect Dis* 2015; **61:** 1807–14.

78 McQuade B, Blair M. Influenza treatment with oseltamivir outside of labeled recommendations. *Am J Health Syst Pharm* 2015; **72:** 112–16.

79 Welch SC, Lam SW, Neuner EA, Bauer SR, Bass SN. High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. *Intensive Care Med* 2015; **41:** 1365–66.

80 Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Feb 1, 2017. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (accessed Feb 23, 2017).

81 Dunning J, Baillie JK, Cao B, Hayden FG, on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. *Lancet Infect Dis* 2014; **14:** 1259–70.

82 Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: future compounds against influenza virus. *J Prev Med Hyg* 2014; **55:** 109–29.

83 Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. *Biomed Res Int* 2014; **2014:** 872370.

84 Kakeya H, Seki M, Izumikawa K, et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. *PLoS One* 2014; **9:** e91293.

85 Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. *Cochrane Database Syst Rev* 2016; **3:** CD010406.

86 Zhang Y, Sun W, Svendsen ER, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. *Crit Care* 2015; **19:** 46.

87 Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. *Antimicrob Agents Chemother* 2015; **59:** 1569–82.

88 Krol E, Rychlowska M, Szewczyk B. Antivirals—current trends in fighting influenza. *Acta Biochim Pol* 2014; **61:** 495–504.

89 Pelegrin M, Naranjo-Gomez M, Piechaczyk M. Antiviral monoclonal antibodies: can they be more than simple neutralizing agents? *Trends Microbiol* 2015; **23:** 653–65.

90 Ramos EL, Mitcham JL, Koller TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. *J Infect Dis* 2015; **211:** 1038–44.

91 Zenilman JM, Fuchs EJ, Hendrix CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. *Antiviral Res* 2015; **123:** 114–19.

92 Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: influenza life-cycle and currently available drugs. *J Prev Med Hyg* 2014; **55:** 69–85.

93 Houser K, Subbarao K. Influenza vaccines: challenges and solutions. *Cell Host Microbe* 2015; **17:** 295–300.

94 Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 influenza season. *MMWR Morb Mortal Wkly Rep* 2015; **64:** 818–25.

95 Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. *Vaccine* 2009; **27:** 1101–10.

96 Black CL, Yue X, Ball SW, et al. Influenza vaccination coverage among health care personnel—United States, 2014–15 influenza season. *MMWR Morb Mortal Wkly Rep* 2015; **64:** 993–99.

97 Jin H, Subbarao K. Live attenuated influenza vaccine. *Curr Top Microbiol Immunol* 2015; **386:** 181–204.

98 Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J* 2006; **25:** 870–79.

99 Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A (H1N1) virus differed by vaccine type during 2013–2014 in the United States. *J Infect Dis* 2016; **213:** 1546–56.

100 Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Euro Surveill* 2016; **21:** 30348.

101 Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. *Expert Rev Vaccines* 2014; **13:** 1571–91.

102 Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev* 2014; **3:** CD001269.

103 Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; **12:** 36–44.

104 Chan TC, Fan-Ngai Hung I, Ka-Hay Luk J, Chu LW, Hon-Wai Chan F. Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. *J Am Med Dir Assoc* 2014; **15:** 226.e1–6.

105 Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. *J Infect Dis* 2012; **206:** 1250–59.

106 Lee WJ, Chen LK, Tang GJ, Lan TY. The impact of influenza vaccination on hospitalizations and mortality among frail older people. *J Am Med Dir Assoc* 2014; **15:** 256–60.

107 Reed C, Kim IK, Singleton JA, et al. Estimated influenza illnesses and hospitalizations averted by vaccination—United States, 2013–14 influenza season. *MMWR Morb Mortal Wkly Rep* 2014; **63:** 1151–54.

108 Neuzil KM. How can we solve the enigma of influenza vaccine-induced protection? *J Infect Dis* 2015; **211:** 1517–18.

109 DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of previous-year vaccination on the efficacy, immunogenicity, and safety of high-dose inactivated influenza vaccine in older adults. *Clin Infect Dis* 2016; **62:** 1092–99.

110 Ding H, Black CL, Ball S, et al. Influenza vaccination coverage among pregnant women—United States, 2014–15 influenza season. *MMWR Morb Mortal Wkly Rep* 2015; **64:** 1000–05.

111 Steinhoff MC, MacDonald N, Pfeifer D, Muglia LJ. Influenza vaccine in pregnancy: policy and research strategies. *Lancet* 2014; **383:** 1611–13.

112 Fell DB, Platt RW, Lanes A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. *Brit J Obstet Gynaec* 2015; **122:** 17–26.

113 Keller-Stanislawski B, Englund JA, Kang G, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. *Vaccine* 2014; **32:** 7057–64.

114 Naleway AL, Irving SA, Henninger ML, et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. *Vaccine* 2014; **32:** 3122–27.

115 Lambert LC, Fauci AS. Influenza vaccines for the future. *N Engl J Med* 2010; **363:** 2036–44.

116 Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. *Hum Vaccin Immunother* 2015; **11:** 553–63.

117 Nolan T, Roy-Ghanta S, Montellano M, et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. *J Infect Dis* 2014; **210:** 545–57.

118 Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One* 2012; **7:** e33536.

119 Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ* 2013; **346:** f794.

120 Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. *Biotechnol J* 2015; **10:** 690–701.

121 Lee YT, Kim KH, Ko EJ, et al. New vaccines against influenza virus. *Clin Exp Vaccine Res* 2014; **3:** 12–28.

122 Yoon SW, Webby RJ, Webster RG. Evolution and ecology of influenza A viruses. *Curr Top Microbiol Immunol* 2014; **385:** 359–75.

123 Salomon R, Webster RG. The influenza virus enigma. *Cell* 2009; **136:** 402–10.

124 Neumann G, Kawaoka Y. Transmission of influenza A viruses. *Virology* 2015; **479–480:** 234–46.

125 Subbarao EK, London W, Murphy BR. A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. *J Virol* 1992; **67:** 1761–64.

126 Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. *Science* 1998; **279:** 393–96.

127 Van Kerkhove MD. Brief literature review for the WHO global influenza research agenda—highly pathogenic avian influenza H5N1 risk in humans. *Influenza Other Respir Viruses* 2013; **7** (suppl 2)**:** 26–33.

128 Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. *N Engl J Med* 2005; **353:** 1374–85.

129 Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H1N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. *N Engl J Med* 2008; **358:** 261–73.

130 Hui DS. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. *Respirology* 2008; **13** (suppl 1)**:** 10–13.

131 Freidl GS, Meijer A, de Bruin E, et al. Influenza at the animal-human interface: a review of the literature for virological evidence of human infection with swine or avian influenza viruses other than A(H5N1). *Euro Surveill* 2014; **19:** 20793.

132 Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med* 2013; **368:** 1888–97.

133 Farooqui A, Liu W, Kelvin DJ, et al. Probable hospital cluster of H7N9 influenza infection. *N Engl J Med* 2016; **374:** 596–98.

134 Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian influenza A(H7N9) virus: a review. *Epidemiol Infect* 2015; **143:** 3359–74.

135 Marjuki H, Mishin VP, Chesnokov AP, et al. Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses. *J Virol* 2015; **89:** 5419–26.

136 Li X, Shi J, Guo J, et al. Genetics, receptor binding property, and transmissibility in mammals of naturally isolated H9N2 avian influenza viruses. *PLoS Pathog* 2014; **10:** e1004508.

137 Pu J, Wang S, Yin Y, et al. Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. *Proc Natl Acad Sci USA* 2015; **112:** 548–53.

138 Rajao DS, Gauger PC, Anderson TK, et al. Novel reassortant human-like H3N2 and H3N1 influenza A viruses detected in pigs are virulent and antigenically distinct from swine viruses endemic to the United States. *J Virol* 2015; **89:** 11213–22.

139 Cauchemez S, Epperson S, Biggerstaff M, Swerdlow D, Finelli L, Ferguson NM. Using routine surveillance data to estimate the epidemic potential of emerging zoonoses: application to the emergence of US swine origin influenza A H3N2v virus. *PLoS Med* 2013; **10:** e1001399.